Literature DB >> 18670669

Financial resources required for tuberculosis control to achieve global targets set for 2015.

Katherine Floyd1, Andrea Pantoja.   

Abstract

OBJECTIVE: To estimate the financial resources required to achieve the 2015 targets for global tuberculosis (TB) control, which have been set within the framework of the Millennium Development Goals (MDGs).
METHODS: The Global Plan to Stop TB, 2006-2015 was developed by the Stop TB Partnership. It sets out what needs to be done to achieve the 2015 targets for global TB control, based on WHO's Stop TB Strategy. Plan costs were estimated using spreadsheet models that included epidemiological, demographic, planning and unit cost data.
FINDINGS: A total of US$ 56 billion is required during the period 2006-2015 (93% for TB-endemic countries, 7% for international technical agencies), increasing from US$ 3.5 billion in 2006 to US$ 6.7 billion in 2015. The single biggest cost (US$ 3 billion per year) is for the treatment of drug-susceptible cases in DOTS programmes. Other major costs are treatment of patients with multi- and extensively drug-resistant TB (MDR-TB and XDR-TB), collaborative TB/HIV activities, and advocacy, communication and social mobilization. Low-income countries account for 41% of total funding needs and 65% of funding needs for TB/HIV. Middle-income countries account for 72% of the funding needed for treatment of MDR-TB and XDR-TB. African countries require the largest increases in funding.
CONCLUSION: Achieving the 2015 global targets set for TB control requires a major increase in funding. To support resource mobilization, comprehensive and costed national plans that are in line with the Global Plan to Stop TB are needed, backed up by robust assessments of the funding that can be raised in each country from domestic sources and the balance that is needed from donors.

Entities:  

Mesh:

Year:  2008        PMID: 18670669      PMCID: PMC2647490          DOI: 10.2471/blt.07.049767

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  14 in total

1.  Resources required for global tuberculosis control.

Authors:  Katherine Floyd; Leopold Blanc; Mario Raviglione; Jong-Wook Lee
Journal:  Science       Date:  2002-03-15       Impact factor: 47.728

2.  Costs of measures to control tuberculosis/HIV in public primary care facilities in Cape Town, South Africa.

Authors:  Harry Peter Hausler; Edina Sinanovic; Lilani Kumaranayake; Pren Naidoo; Hennie Schoeman; Barbara Karpakis; Peter Godfrey-Faussett
Journal:  Bull World Health Organ       Date:  2006-07       Impact factor: 9.408

3.  What will it cost to attain the health MDGs?

Authors:  Anders Nordström; Tessa Tan-Torres Edejer; David Evans
Journal:  Bull World Health Organ       Date:  2007-04       Impact factor: 9.408

4.  Planning to improve global health: the next decade of tuberculosis control.

Authors:  Dermot Maher; Chris Dye; Katherine Floyd; Andrea Pantoja; Knut Lonnroth; Alasdair Reid; Eva Nathanson; Thad Pennas; Uli Fruth; Jane Cunningham; Heather Ignatius; Mario C Raviglione; Irene Koek; Marcos Espinal
Journal:  Bull World Health Organ       Date:  2007-05       Impact factor: 9.408

5.  Financing tuberculosis control: the role of a global financial monitoring system.

Authors:  Katherine Floyd; Andrea Pantoja; Christopher Dye
Journal:  Bull World Health Organ       Date:  2007-05       Impact factor: 9.408

6.  Prospects for worldwide tuberculosis control under the WHO DOTS strategy. Directly observed short-course therapy.

Authors:  C Dye; G P Garnett; K Sleeman; B G Williams
Journal:  Lancet       Date:  1998-12-12       Impact factor: 79.321

7.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data.

Authors:  Alan D Lopez; Colin D Mathers; Majid Ezzati; Dean T Jamison; Christopher J L Murray
Journal:  Lancet       Date:  2006-05-27       Impact factor: 79.321

8.  A financial road map to scaling up essential child health interventions in 75 countries.

Authors:  Karin Stenberg; Benjamin Johns; Robert W Scherpbier; Tessa Tan-Torres Edejer
Journal:  Bull World Health Organ       Date:  2007-04       Impact factor: 9.408

9.  Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines.

Authors:  Thelma E Tupasi; Rajesh Gupta; Ma Imelda D Quelapio; Ruth B Orillaza; Nona Rachel Mira; Nellie V Mangubat; Virgil Belen; Nida Arnisto; Lualhati Macalintal; Michael Arabit; Jaime Y Lagahid; Marcos Espinal; Katherine Floyd
Journal:  PLoS Med       Date:  2006-09       Impact factor: 11.069

10.  Programme costs in the economic evaluation of health interventions.

Authors:  Benjamin Johns; Rob Baltussen; Raymond Hutubessy
Journal:  Cost Eff Resour Alloc       Date:  2003-02-26
View more
  12 in total

Review 1.  Drug-resistant tuberculosis: a worldwide epidemic poses a new challenge.

Authors:  Robert Loddenkemper; Barbara Hauer
Journal:  Dtsch Arztebl Int       Date:  2010-01-07       Impact factor: 5.594

Review 2.  Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.

Authors:  E L Corbett; P MacPherson
Journal:  Int J Tuberc Lung Dis       Date:  2013-09       Impact factor: 2.373

3.  Implementing the global plan to stop TB, 2011-2015--optimizing allocations and the Global Fund's contribution: a scenario projections study.

Authors:  Eline L Korenromp; Philippe Glaziou; Christopher Fitzpatrick; Katherine Floyd; Mehran Hosseini; Mario Raviglione; Rifat Atun; Brian Williams
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

4.  Identification of potential inhibitor targeting enoyl-acyl carrier protein reductase (InhA) in Mycobacterium tuberculosis: a computational approach.

Authors:  V Shanthi; K Ramanathan
Journal:  3 Biotech       Date:  2013-06-18       Impact factor: 2.406

5.  Towards cash transfer interventions for tuberculosis prevention, care and control: key operational challenges and research priorities.

Authors:  Delia Boccia; Debora Pedrazzoli; Tom Wingfield; Ernesto Jaramillo; Knut Lönnroth; James Lewis; James Hargreaves; Carlton A Evans
Journal:  BMC Infect Dis       Date:  2016-06-21       Impact factor: 3.090

6.  Cost-effectiveness of screening for active cases of tuberculosis in Flanders, Belgium.

Authors:  G Suzanne A Smit; Ludwig Apers; Wouter Arrazola de Onate; Philippe Beutels; Pierre Dorny; An-Marie Forier; Kristien Janssens; Jean Macq; Ruud Mak; Sandrina Schol; Dirk Wildemeersch; Niko Speybroeck; Brecht Devleesschauwer
Journal:  Bull World Health Organ       Date:  2016-11-03       Impact factor: 9.408

7.  A randomized controlled study of socioeconomic support to enhance tuberculosis prevention and treatment, Peru.

Authors:  Tom Wingfield; Marco A Tovar; Doug Huff; Delia Boccia; Rosario Montoya; Eric Ramos; Sumona Datta; Matthew J Saunders; James J Lewis; Robert H Gilman; Carlton A Evans
Journal:  Bull World Health Organ       Date:  2017-02-09       Impact factor: 9.408

8.  Designing and implementing a socioeconomic intervention to enhance TB control: operational evidence from the CRESIPT project in Peru.

Authors:  Tom Wingfield; Delia Boccia; Marco A Tovar; Doug Huff; Rosario Montoya; James J Lewis; Robert H Gilman; Carlton A Evans
Journal:  BMC Public Health       Date:  2015-08-21       Impact factor: 3.295

9.  [Nephrocalcinosis complicating miliary tuberculosis in an infant].

Authors:  Jaouad El Maghraoui; Fatima Zahrae Souilmi; Mohamed Hbibi; Tarik Sqalli Houssaini; Mustapha Hida
Journal:  Pan Afr Med J       Date:  2015-04-29

10.  Feasibility of tuberculosis treatment monitoring by video directly observed therapy: a binational pilot study.

Authors:  R S Garfein; K Collins; F Muñoz; K Moser; P Cerecer-Callu; F Raab; P Rios; A Flick; M L Zúñiga; J Cuevas-Mota; K Liang; G Rangel; J L Burgos; T C Rodwell; K Patrick
Journal:  Int J Tuberc Lung Dis       Date:  2015-09       Impact factor: 2.373

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.